Damora Therapeutics is a cash-burning pre-commercial biotechnology company with below-minimum quality metrics — negative free cash flow, no competitive moat, and a 2/9 financial health score — that has reached deeply oversold conditions (RSI 15) with a volume surge suggesting potential capitulation; the 116% analyst-implied upside reflects pipeline optimism from light coverage, and the investment case depends entirely on catalyst delivery rather than current business fundamentals.
Thesis pillars
- Large Analyst Implied Upside→Stable
- Quality Well Below Investment Floor→Stable
- Capitulation Oversold Technical Setup→Stable
- +1 more pillar — see the Why tab for full reasoning
Damora Therapeutics, Inc. (DMRA) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $25.36: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the... Read more
Sell if holding. Engine safety override at $25.36: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Score 5.5/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-29Recent Developments — Damora Therapeutics, Inc.
Latest news
- NEWS Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target — benzinga Jun 12, 2026 positive
- NEWS HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45 — benzinga Jun 11, 2026 positive
- NEWS Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35 — benzinga May 28, 2026 positive
- NEWS Damora Therapeutics Says On Track For First Regulatory Submission For DMR-001 In Mid-2026 — benzinga May 12, 2026 positive
- NEWS Damora Therapeutics Q1 EPS $(0.62) Misses $(0.40) Estimate — benzinga May 12, 2026 negative
Generated 2026-06-30T02:18:55Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $25.36: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Prior stop was $23.58. Score 5.5/10, moderate confidence.
Take-profit target: $37.74 (+48.8% upside). Prior stop was $23.58. Stop-loss: $23.58.
Quality below floor (1.2 < 4.0).
Damora Therapeutics, Inc. trades at a P/E of N/A (forward -12.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
13 analysts cover DMRA with a consensus score of 4.3/5. Average price target: $43.
What does Damora Therapeutics, Inc. do?Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders...
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.